

TABLE 1 Demographic Characteristics of the Study Population

Variable		Result
Sex	Female	13/26 (50)
Age (years)		9.5 [8.0; 11.5] (min 6-max 18)
Overweight/obesity (IOTF criteria >25)		6/26 (23)
Age at 1st wheezing episode (years)		1.4 [0.5; 3.6]
Environment		
Smoking during pregnancy		5/26 (19)
Post-natal passive smoking		10/26 (38)
Living area	Rural	7/26 (27)
	Semi-rural	9/26 (35)
	Urban	10/26 (38)
Mold, dust at home		6/26 (23)
Pets		
	Cat	10/26 (38)
	Dog	12/26 (46)
	Rabbit	3/26 (12)
	Chicken	2/26 (8)
	Hamster	1/26 (4)
Comorbidities		
Gastroesophageal reflux disease (GERD)		1/26 (4)
Ear-nose-throat involvement (polyps, nasal obstruction, otitis media)		4/26 (15)
Obstructive Sleep Apnea Syndrome		3/26 (12)
Atopy-allergy		

Family History		24/26 (92)
Prick-test or serum IgE (positive for pneumallergens)	House Dust Mite	14/26 (48)
	Pollen	10/26 (38)
	Mould	2/26 (8)
	Dog dander	5/26 (19)
	Cat dander	4/26 (15)
Atopic dermatitis		11/26 (42)
Allergic rhino-conjunctivitis		16/26 (62)
Food Allergy		8/26 (31)
Treatment		
SABA (as required)		26/26 (100)
ICS only		2/26 (8)
LTRA		13/26 (50)
Combined ICS + LABA		24/26 (92)
Omalizumab		3/26 (12)
Theophylline		1/26 (4)
Severity (GINA level)		
Moderate persistent, Level 3		4/26 (15.4)
Severe persistent, Level 4		17/26 (65.4)
Severe persistent, Level 5		5/26 (19.2)
Asthma Control		
≥ 1 medical consultation for asthma exacerbation in the previous year		19/23 (83)
≥ 1 hospitalization for asthma in the previous year		12/24 (50)

≥ 1 hospitalization in intensive care for asthma, ever		2/25 (8)
Control according to GINA score	Well controlled	2/25 (8)
	Partly controlled	11/25 (44)
	Uncontrolled	12/25 (48)
ACT score < 20 (uncontrolled)		15/25 (60)
Baseline FEV1 <80% of predicted value		4/26 (15)

Note: data are presented as n/N (%), median [IQR1; IQR3].

Abbreviations: ACT, Asthma Control Test; ICS, inhaled corticosteroids; FEV1, Forced Expiratory Volume in one second; IOTF, International Obesity Taskforce; LABA, long-acting beta-agonist; LTRA, leukotriene receptor antagonist SABA, short-acting beta-agonist